TY - JOUR
T1 - Cognitive decline in adults with amnestic mild cognitive impairment and high amyloid-β
T2 - Prodromal Alzheimer's disease?
AU - Lim, Yen Ying
AU - Ellis, Kathryn A.
AU - Harrington, Karra
AU - Pietrzak, Robert H.
AU - Gale, Joanne
AU - Ames, David
AU - Bush, Ashley I.
AU - Darby, David
AU - Martins, Ralph N.
AU - Masters, Colin L.
AU - Rowe, Christopher C.
AU - Savage, Greg
AU - Szoeke, Cassandra
AU - Villemagne, Victor L.
AU - Maruff, Paul
AU - The AIBL Research Group
PY - 2013
Y1 - 2013
N2 - We aimed to characterize the nature and magnitude of cognitive decline in a group of adults with amnestic mild cognitive impairment (aMCI) with high and low levels of amyloid-β (Aβ) in relation to healthy older adults with low Aβ levels. Healthy older adults and adults with aMCI enrolled in the Australian Imaging, Biomarker, and Lifestyle study, completed the CogState brief battery at baseline and 18 months, and underwent positron emission tomography neuroimaging for Aβ at baseline. In this study, we included adults with MCI who had been classified as having high and low levels of Aβ and healthy older adults who had been classified as having low levels of Aβ. Linear model analyses adjusted for baseline cognitive function indicated that relative to healthy older adults with low Aβ, adults with aMCI and high Aβ showed greater decline in working memory and in verbal and visual episodic memory at 18 months. Adults with aMCI and low Aβ also showed greater decline in working memory; however they did not evidence any decline in episodic memory at 18 months. The results of our study suggests that relative to healthy older adults and adults with aMCI with low Aβ, adults with aMCI and high levels of Aβ showed faster rates of decline on measures of episodic memory over 18 months, and this was approximately twice that observed previously for healthy older adults with high Aβ levels.
AB - We aimed to characterize the nature and magnitude of cognitive decline in a group of adults with amnestic mild cognitive impairment (aMCI) with high and low levels of amyloid-β (Aβ) in relation to healthy older adults with low Aβ levels. Healthy older adults and adults with aMCI enrolled in the Australian Imaging, Biomarker, and Lifestyle study, completed the CogState brief battery at baseline and 18 months, and underwent positron emission tomography neuroimaging for Aβ at baseline. In this study, we included adults with MCI who had been classified as having high and low levels of Aβ and healthy older adults who had been classified as having low levels of Aβ. Linear model analyses adjusted for baseline cognitive function indicated that relative to healthy older adults with low Aβ, adults with aMCI and high Aβ showed greater decline in working memory and in verbal and visual episodic memory at 18 months. Adults with aMCI and low Aβ also showed greater decline in working memory; however they did not evidence any decline in episodic memory at 18 months. The results of our study suggests that relative to healthy older adults and adults with aMCI with low Aβ, adults with aMCI and high levels of Aβ showed faster rates of decline on measures of episodic memory over 18 months, and this was approximately twice that observed previously for healthy older adults with high Aβ levels.
KW - Alzheimer’s disease
KW - amyloid-B
KW - cognitive change
KW - cognitive neuropsychology
KW - mild cognitive impairment
UR - http://www.scopus.com/inward/record.url?scp=84873657034&partnerID=8YFLogxK
U2 - 10.3233/JAD-121771
DO - 10.3233/JAD-121771
M3 - Article
C2 - 23160011
AN - SCOPUS:84873657034
SN - 1387-2877
VL - 33
SP - 1167
EP - 1176
JO - Journal of Alzheimer's Disease
JF - Journal of Alzheimer's Disease
IS - 4
ER -